Pirfenidone treatment of idiopathic pulmonary fibrosis

Ye Gan, Erica L Herzog, Richard H Gomer, Ye Gan, Erica L Herzog, Richard H Gomer

Abstract

Idiopathic pulmonary fibrosis (IPF) is a discrete clinicopathologic entity defined by the presence of usual interstitial pneumonia on high-resolution CT scan and/or open lung biopsy and the absence of an alternate diagnosis or exposure explaining these findings. There are currently no FDA-approved therapies available to treat this disease, and the 5-year mortality is ∼80%. The pyridone derivative pirfenidone has been studied extensively as a possible therapeutic agent for use in this deadly disease. This review will present the unique clinical features and management issues encountered by physicians caring for IPF patients, including the poor response to conventional therapy. The biochemistry and preclinical efficacy of pirfenidone will be discussed along with a comprehensive review of the clinical efficacy, safety, and side effects and patient-centered foci such as quality of life and tolerability. It is hoped that this information will lend insight into the complex issues surrounding the use of pirfenidone in IPF and lead to further investigation of this agent as a possible therapy in this devastating disease.

Keywords: clinical trials; fibrosis; pirfenidone.

Figures

Figure 1
Figure 1
The structure of pirfenidone. After ingestion, the CH3 group at the bottom of the structure is rapidly metabolized to primarily COOH and to a lesser extent OH.

References

    1. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol. 2004;4(8):583–594.
    1. American Thoracic Society. European Respiratory Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, 2001 Jun and by the ERS Executive Committee, 2001 Jun. Am J Respir Crit Care Med. 2002;165(2):277–304.
    1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810–816.
    1. Yuksel M, Ozyurtkan MO, Bostanci K, Ahiskali R, Kodalli N. Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann Thorac Surg. 2006;82(1):336–338.
    1. Castelino FV, Goldberg H, Dellaripa PF. The impact of rheumatological evaluation in the management of patients with interstitial lung disease. Rheumatology (Oxford) 2010 Aug 4; Epub ahead of print.
    1. Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3(4):315–321.
    1. Swigris JJ, Wamboldt FS, Behr J, et al. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference. Thorax. 2010;65(2):173–177.
    1. Nava S, Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax. 1999;54(5):390–395.
    1. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest. 1998;113(2):396–400.
    1. Jezek V, Fucik J, Michaljanic A, Jezkova L. The prognostic significance of functional tests in cryptogenic fibrosing alveolitis. Bull Eur Physiopathol Respir. 1980;16(6):711–720.
    1. Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;174(7):803–809.
    1. Ryu JH, Daniels CE. Advances in the management of idiopathic pulmonary fibrosis. F1000 Med Rep. 2010;2:28.
    1. Tobin RW, Pope CE, 2nd, Pellegrini CA, Emond MJ, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158(6):1804–1808.
    1. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27(1):136–142.
    1. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129(3):794–800.
    1. Gaude GS. Pulmonary manifestations of gastroesophageal reflux disease. Ann Thorac Med. 2009;4(3):115–123.
    1. Nathan SD, Basavaraj A, Reichner C, et al. Prevalence and impact of coronary artery disease in idiopathic pulmonary fibrosis. Respir Med. 2010;104(7):1035–1041.
    1. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008;178(12):1257–1261.
    1. Panos RJ, Mortenson RL, Niccoli SA, King TE., Jr Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990;88(4):396–404.
    1. Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009;136(3):772–778.
    1. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161(1):5–8.
    1. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–643.
    1. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2007;132(5):1652–1658.
    1. Martinez FJ, Safrin S, Weycker D, et al. IPF Study Group The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963–967.
    1. Homma S, Sakamoto S, Kawabata M, et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med. 2005;44(11):1144–1150.
    1. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128(3):1475–1482.
    1. Algar FJ, Espinosa D, Moreno P, et al. Results of lung transplantation in idiopathic pulmonary fibrosis patients. Transplant Proc. 2010;42(8):3211–3213.
    1. Mackay LS, Anderson RL, Parry G, Lordan J, Corris PA, Fisher AJ. Pulmonary fibrosis: rate of disease progression as a trigger for referral for lung transplantation. Thorax. 2007;62(12):1069–1073.
    1. Wuyts WA, Thomeer M, Dupont LJ, Verleden GM. An algorithm for referral of patients with IPF for lung transplantation. Thorax. 2008;63(3):292. author reply 292.
    1. Neurohr C, Huppmann P, Thum D, et al. Munich Lung Transplant Group Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis. Transpl Int. 2010;23(9):887–896.
    1. Fang A, Studer S, Kawut SM, et al. for the Lung Transplant Outcomes Group Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pumonary fibrosis. Chest. 2010 Sep 23; Epub ahead of print.
    1. Raghu G, Brown KK, Bradford WZ, et al. Idiopathic Pulmonary Fibrosis Study Group A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350(2):125–133.
    1. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341(17):1264–1269.
    1. King TE, Jr, Albera C, Bradford WZ, et al. INSPIRE Study Group Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009;374(9685):222–228.
    1. King TE, Jr, Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177(1):75–81.
    1. Behr J, Noble PW. Clinical trials in interstitial lung disease. European Respiratory Monograph. 2009;46:67–84.
    1. Demedts M, Behr J, Buhl R, et al. IFIGENIA Study Group High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229–2242.
    1. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008;178(9):948–955.
    1. Jackson RM, Fell CD. Etanercept for idiopathic pulmonary fibrosis: lessons on clinical trial design. Am J Respir Crit Care Med. 2008;178(9):889–891.
    1. Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW, Idiopathic Pulmonary Fibrosis Clinical Research Network A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620–628.
    1. Gadekar SM. 5-Methyl-1-phenyl-2-(1H)-pyridone compositions and methods of use. 1976. Aug 10, inventor. US patent 3,974,281.
    1. Margolin SB. Composition and method for reparation and prevention of fibrotic lesions. 1994. May 10, inventor. US patent 5,310,562.
    1. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995;125(6):779–785.
    1. Lee BS, Margolin SB, Nowak RA. Pirfenidone: a novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab. 1998;83(1):219–223.
    1. Zhang S, Shiels IA, Ambler JS, Taylor SM. Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Aust N Z J Ophthalmol. 1998;26(Suppl 1):S74–S76.
    1. Margolin SB. Treatment of cytokine growth factor caused disorders. 2000. Jul 18, inventor. US patent 6,090,822.
    1. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;289(1):211–218.
    1. Nangaku M, Izuhara Y, Takizawa S, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol. 2007;27(12):2548–2554.
    1. Kaneko M, Inoue H, Nakazawa R, et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol. 1998;113(1):72–76.
    1. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol. 1999;276(2 Pt 1):L311–L318.
    1. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol. 2002;446(1–3):177–185.
    1. Oku H, Shimizu T, Kawabata T, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590(1–3):400–408.
    1. Visner GA, Liu F, Bizargity P, et al. Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation. 2009;88(3):330–338.
    1. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem. 2000;204(1–2):119–126.
    1. Shi S, Wu J, Chen H, Wu J, Zeng F. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007;47(10):1268–1276.
    1. Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279–285.
    1. Suga H, Teraoka S, Ota K, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol. 1995;47(4):287–291.
    1. Shimizu T, Fukagawa M, Kuroda T, et al. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy. Kidney Int Suppl. 1997;63:S239–S243.
    1. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 1998;54(1):99–109.
    1. Tada S, Nakamuta M, Enjoji M, et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol. 2001;28(7):522–527.
    1. Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm. 2010;7(10):1438–1445.
    1. Shetlar MR, Shetlar DJ, Bloom RF, Shetlar CL, Margolin SB. Involution of keloid implants in athymic mice treated with pirfenidone or with triamcinolone. J Lab Clin Med. 1998;132(6):491–496.
    1. Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol. 1998;20(12):685–695.
    1. Arumugam TV, Shiels IA, Margolin SB, Taylor SM, Brown L. Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine. Clin Exp Pharmacol Physiol. 2002;29(11):996–1000.
    1. Giri SN, Margolin SB. Effects of topical application of pirfenidone ointment on thermoplasty-induced acute lameness in a double-blind and acute and chronic lameness of musculoskeletal origin in an open multi-centered field trial in horses. Res Commun Mol Pathol Pharmacol. 2005;117–118:47–63.
    1. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1061–1069.
    1. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–1047.
    1. Mathai SC, Polito AJ. The questionable efficacy of pirfenidone in IPF. Am J Respir Crit Care Med. 2005;172(9):1228.
    1. Levitt J, Gould MK. Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF. Am J Respir Crit Care Med. 2005;172(9):1228–1229. author reply 1229.
    1. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–829.
    1. Collard HR. Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J. 2010;35(4):728–729.
    1. Swigris J, Fairclough D. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36(3):695–696. author reply 696–698.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren